Illumina, Inc. $ILMN Shares Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.4% in the 1st quarter, Holdings Channel reports. The firm owned 24,459 shares of the life sciences company’s stock after acquiring an additional 3,270 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Illumina were worth $3,015,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. HighPoint Advisor Group LLC lifted its holdings in shares of Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after buying an additional 85 shares during the last quarter. Toronto Dominion Bank grew its stake in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after buying an additional 92 shares during the last quarter. Panagora Asset Management Inc. grew its stake in Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its position in Illumina by 4.2% in the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after buying an additional 99 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This represents a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock worth $155,710,908 in the last quarter. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $192.98 on Wednesday. The company has a 50-day simple moving average of $173.22 and a 200 day simple moving average of $146.03. The company has a market capitalization of $29.20 billion, a P/E ratio of 35.09, a PEG ratio of 2.80 and a beta of 1.47. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $199.14.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $0.97 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ILMN shares. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Citigroup upped their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Canaccord Genuity Group increased their price objective on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Guggenheim lifted their price objective on shares of Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Sanford C. Bernstein initiated coverage on shares of Illumina in a research note on Friday, June 26th. They set a “market perform” rating and a $185.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $156.88.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.